Evidence map›Paper›PMID 35719993›Full record

ArticleFrontiers in oncology2022

Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy.

Amandine Moretton, Jana Slyskova, Marwan E Simaan, Emili A Arasa-Verge, Mathilde Meyenberg, D Alonso Cerrón-Infantes, Miriam M Unterlass, Joanna I Loizou

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amandine MorettonCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Jana SlyskovaCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Marwan E SimaanCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Emili A Arasa-VergeCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Mathilde MeyenbergCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
D Alonso Cerrón-InfantesCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Miriam M UnterlassCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Joanna I LoizouCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin induces DNA crosslinks that are highly cytotoxic. Hence, platinum complexes are frequently used in the treatment of a broad range of cancers. Efficiency of cisplatin treatment is limited by the tumor-specific DNA damage response to the generated lesions. We reasoned that better tools to investigate the repair of DNA crosslinks induced by cisplatin would therefore be highly useful in addressing drug limitations. Here, we synthesized a series of cisplatin derivatives that are compatible with click chemistry, thus allowing visualization and isolation of DNA-platinum crosslinks from cells to study cellular responses. We prioritized one alkyne and one azide Pt(II) derivative, Pt-alkyne-53 and Pt-azide-64, for further biological characterization. We demonstrate that both compounds bind DNA and generate DNA lesions and that the viability of treated cells depends on the active DNA repair machinery. We also show that the compounds are clickable with both a fluorescent probe as well as biotin, thus they can be visualized in cells, and their ability to induce crosslinks in genomic DNA can be quantified. Finally, we show that Pt-alkyne-53 can be used to identify DNA repair proteins that bind within its proximity to facilitate its removal from DNA. The compounds we report here can be used as valuable experimental tools to investigate the DNA damage response to platinum complexes and hence might shed light on mechanisms of chemoresistance.

Indexed as

chemoresistancechemotherapycisplatinclick chemistryDNA crosslinksDNA DamageDNA repair

Identifiers

PMID35719993
PMCPMC9202558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.